SEC Form 4 · accession 0001209191-16-090969
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carl Goldfischer
Director
Period of report
Jan 12, 2016
Accepted (ET)
Jan 12, 2016 · 4:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF2 | Jan 12, 2016 | P | 545,166 | $9.00 | A | 3,370,562 | I | See Footnote |
| Common Stock, par value $0.0001 per shareF3 | Jan 12, 2016 | P | 10,389 | $9.00 | A | 3,380,951 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reports the purchase of shares in the underwritten public offering of common stock of Epizyme, Inc.
- F2Represents shares held by Bay City Capital Fund V, L.P. ("Fund V"); and indirect interests of Bay City Capital ("BCC"), the manager of Bay City Capital Management V LLC ("Management V"), and Management V, the general partner of Fund V. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management V each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
- F3Represents shares held by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"); and indirect interests of BCC, the manager of Management V, and Management V, the general partner of Fund V. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management V each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.